Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC)
- Main trialPhase 1/2
- “This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For…”In the company’s words, NCT07941362 on ClinicalTrials.gov
Other drugs for Pancreatic Ductal Adenocarcinoma (PDAC)
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up1
- 31 Jul 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 17 NovNew trial: none to Phase 1/2 · ClinicalTrials.gov NCT07941362
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 31 Jul 2029 | 177Lu-ACT319 in FAP Expressing Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026